Table 3 Reported risk factors for ICI-AKD
Study (date) | Criteria for ICI-AKDa | No. patients with ICI-AKD (%) | No. patients biopsied (%) | No. patients with ATIN on biopsy (%) | Risk factors for ICI-AKD | |||
|---|---|---|---|---|---|---|---|---|
PPI use | Extrarenal IRAE | Lower baseline eGFR | Combination ICI therapy | |||||
Seethapathy et al. (2019)77 | SCr ≥1.5× baseline for ≥3 days; expert adjudicated | 30 (3) | 1 (3) | 1 (100) | Risk increased | Not assessedb | Risk not increased | Risk not increased |
Cortazar et al. (2020)79 | SCr ≥2× baseline or need for KRT | 138 (100) | 60 (43) | 56 (93) | Risk increased | Not assessed | Risk increased | Risk increased |
Gupta et al. (2021)7 | Expert adjudicated ICI-AKI and either SCr ≥2× baseline or SCr ≥1.5× baseline and ATIN on kidney biopsy, ICI held due to concern for ICI-AKI or treated with glucocorticoids | 429 (100) | 151 (35) | 125 (83) | Risk increased | Risk increased | Risk increased | Risk not increased |
Koks et al. (2021)75 | SCr ≥1.5× baseline on at least two consecutive checks or need for KRT and absence of alternative cause, and at least one of sterile pyuria, eosinophilia or recent or concomitant non-kidney IRAEc | 32 (4.7)d | 1 (3) | 1 (100) | Risk increased | Not assessed | Risk not increased | Risk not increased |
